The University of Chicago Header Logo

Connection

Gini Fleming to Gastrointestinal Diseases

This is a "connection" page, showing publications Gini Fleming has written about Gastrointestinal Diseases.
Connection Strength

0.108
  1. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7.
    View in: PubMed
    Score: 0.108
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.